It's hard to imagine that the brain trust on this board...can evaluate the study data...and understand it and that the analysts can't...Given the hard statistics in the response data Ponatinib will outperform current drugs in a first use setting...period...end of story....So if your an analyst and you understand the huge potential in front line...how the hell are you worrying about 2nd or 3rd line uptake...Is this board... THAT.. ahead of the curve ?....
News 
Market Data 
Discover 
AI
